Pfizer Inc. stock price
Today's NYSE:PFE chart, history & news
Price:
38.57
USD
Change:
+0.97 (2.58%)
Key stats
| Price open | 37.99 |
|---|---|
| Previous close | 37.6 |
| Market cap | 215.13B |
| Volume | 52.83M |
| Day high | 38.7 |
| Day low | 37.805 |
| Year high | 42.62 |
| Year low | 30.65 |
| Year to date change | 8.50% |
| P/E ratio | 22.56 |
Company Profile
Fundamentals
Insider Information
News
About Pfizer Inc.
Charles Pfizer and Charles Erhart founded Charles Pfizer & Company in 1849 in Brooklyn, New York. At the time, the company focused on producing fine chemicals. After its launch into the pharmaceutical sector, the company first produced santonin for the treatment of intestinal worms. The company later diversified its operations into production of disinfectants, painkillers, and preservatives. Charles Pfizer & Company Inc. was incorporated in New Jersey in 1900.
Presently, Pfizer is a huge multinational healthcare company focused on developing, manufacturing, and selling healthcare products. Specifically, the company produces medicines and vaccines targeting various therapeutic sectors. Other products under the Pfizer brand include dietary supplements, pain management products, gastrointestinal products, and products focused on personal care. The company works in close collaboration with industry greats like Merc & Co. Inc., and Bristol-Myers Squibb among others.
Pfizer operates from New York as its headquarters. The company’s shares trade on the New York Stock Exchange with PFE as its symbol. PFE is a constituent of DJIA, S&P 100, and S&P 500 components.
Company information
Company name
Pfizer Inc.
Exchange
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Employees
88,300
CEO
Albert Bourla
Address
235 E 42nd St, New York, New York, 10017-5703
Country
United States
Contact information
12125732323
Website
https://www.pfizer.com/
Latest Pfizer Inc. news
18th February
What to make of Pfizer, Moderna insiders dumping stock?
Pfizer Inc. earnings reports (2020)
| Q3 2020 | Q2 2020 | Q1 2020 | |
|---|---|---|---|
| Actual EPS | 0.72 | 0.78 | 0.8 |
| Consensus EPS | 0.71 | 0.68 | 0.73 |
| Announce Time | BTO | BTO | BTO |
| Number of Estimates | 13 | 10 | 9 |
| EPS Surprise Dollar | 0.01 | 0.1 | 0.07 |
| EPS Report Date | 27-10-2020 | 28-07-2020 | 28-04-2020 |
| Fiscal End Date | 30-09-2020 | 30-06-2020 | 31-03-2020 |
| Year Ago | 0.75 | 0.8 | 0.85 |
| Year Ago % Change | -4% | -2.5% | -5.88% |
Pfizer Inc. earnings reports (2019)
| Q4 2019 | Q3 2019 | Q2 2019 | |
|---|---|---|---|
| Actual EPS | 0.55 | 0.75 | 0.8 |
| Consensus EPS | 0.58 | 0.62 | 0.75 |
| Announce Time | BTO | BTO | BTO |
| Number of Estimates | 11 | 10 | 10 |
| EPS Surprise Dollar | -0.03 | 0.13 | 0.05 |
| EPS Report Date | 28-01-2020 | 29-10-2019 | 29-07-2019 |
| Fiscal End Date | 31-12-2019 | 30-09-2019 | 30-06-2019 |
| Year Ago | 0.64 | 0.78 | 0.81 |
| Year Ago % Change | -14.06% | -3.85% | -1.23% |
Pfizer Inc. income statements (2020) (USD)
| November 2020 | June 2020 | June 2020 | March 2020 | |
|---|---|---|---|---|
| Total Revenue | 12.13B | 11.80B | 11.80B | 12.03B |
| Cost of Revenue | 2.53B | 3.17B | 3.17B | 3.25B |
| Gross Profit | 9.60B | 8.63B | 8.63B | 8.78B |
| Research & Development | 2.36B | 2.13B | 2.13B | 1.73B |
| Selling General & Admin | 3.02B | 2.97B | 2.97B | 2.86B |
| Operating Expense | 8.80B | 8.27B | 8.27B | 7.84B |
| Operating Income | 3.33B | 3.53B | 3.53B | 4.19B |
| Other Income Expense Net | 0 | 419M | 419M | -308M |
| EBIT | 3.33B | 3.53B | 3.53B | 4.19B |
| Interest Income | 0 | 372M | 372M | 390M |
| Pretax Income | 2.18B | 3.95B | 3.95B | 3.89B |
| Income Tax | -26M | 519M | 519M | 475M |
| Minority Interest | 8M | 8M | 8M | 9M |
| Net Income | 2.19B | 3.43B | 3.43B | 3.40B |
| Net Income Basic | 2.19B | 3.43B | 3.43B | 3.40B |
Pfizer Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 12.69B | 12.68B | 13.26B | 13.12B |
| Cost of Revenue | 3.62B | 3.79B | 3.74B | 3.59B |
| Gross Profit | 9.07B | 8.89B | 9.53B | 9.52B |
| Research & Development | 2.81B | 2.28B | 1.83B | 1.70B |
| Selling General & Admin | 4.21B | 3.24B | 3.49B | 3.33B |
| Operating Expense | 10.64B | 9.31B | 9.06B | 8.62B |
| Operating Income | 2.04B | 3.37B | 4.20B | 4.50B |
| Other Income Expense Net | -3.55B | 7.36B | -62M | -176M |
| EBIT | 2.04B | 3.37B | 4.20B | 4.50B |
| Interest Income | 415M | 409M | 389M | 361M |
| Pretax Income | -1.51B | 10.73B | 4.14B | 4.32B |
| Income Tax | -1.18B | 3.05B | -0.92B | 433M |
| Minority Interest | 10M | 4M | 10M | 6M |
| Net Income | -337M | 7.68B | 5.05B | 3.88B |
| Net Income Basic | -337M | 7.68B | 5.05B | 3.88B |
Pfizer Inc. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | 13.98B | 13.30B | 13.47B | 12.91B |
| Cost of Revenue | 4.30B | 3.93B | 4.09B | 3.73B |
| Gross Profit | 9.68B | 9.37B | 9.38B | 9.18B |
| Research & Development | 2.44B | 2B | 1.79B | 1.74B |
| Selling General & Admin | 3.99B | 3.48B | 3.53B | 3.40B |
| Operating Expense | 10.72B | 9.40B | 9.40B | 8.86B |
| Operating Income | 3.26B | 3.90B | 4.06B | 4.05B |
| Other Income Expense Net | -4.2B | 281M | 464M | 79M |
| EBIT | 3.26B | 3.90B | 4.06B | 4.05B |
| Interest Income | 370M | 310M | 326M | 310M |
| Pretax Income | -0.95B | 4.18B | 4.53B | 4.13B |
| Income Tax | -563M | 66M | 648M | 556M |
| Minority Interest | 11M | 8M | 7M | 9M |
| Net Income | -394M | 4.11B | 3.87B | 3.56B |
| Net Income Basic | -394M | 4.11B | 3.87B | 3.56B |
Pfizer Inc. income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | 13.70B | 13.17B | 12.90B |
| Cost of Revenue | 4.39B | 3.96B | 3.81B |
| Gross Profit | 9.32B | 9.21B | 9.08B |
| Research & Development | 2.30B | 1.85B | 1.77B |
| Selling General & Admin | 4.53B | 3.48B | 3.41B |
| Operating Expense | 11.21B | 9.29B | 8.99B |
| Operating Income | 2.49B | 3.88B | 3.90B |
| Other Income Expense Net | -1.54B | -296M | -88M |
| EBIT | 2.49B | 3.88B | 3.90B |
| Interest Income | 329M | 320M | 312M |
| Pretax Income | 0.95B | 3.59B | 3.82B |
| Income Tax | -11.34B | 727M | 739M |
| Minority Interest | 15M | 18M | 5M |
| Net Income | 12.27B | 2.84B | 3.07B |
| Net Income Basic | 12.27B | 2.84B | 3.07B |
Pfizer Inc. balance sheet (2020) (USD)
| November 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Current Cash | 10.50B | 1.80B | 2.15B |
| Receivables | 10.01B | 9.13B | 9.88B |
| Inventory | 9.30B | 8.56B | 8.42B |
| Current Assets | 47.74B | 46.42B | 34.74B |
| Other Current Assets | 6.52B | 5.94B | 6.08B |
| Short Term Investments | 6.52B | 20.99B | 8.20B |
| Long Term Investments | 131.24B | 18.72B | 18.22B |
| Property/Plant Equipment | 14.40B | 14.11B | 14.04B |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 30.93B | 33.54B | 34.46B |
| Tangible Assets (Net) | -25.57B | -152.77B | -152.18B |
| Other Assets | 7B | 4.33B | 4.17B |
| Total Assets | 178.98B | 177.93B | 166.34B |
| Accounts Payable | 4.14B | 3.87B | 3.97B |
| Other Current Liabilities | 16.65B | 14.32B | 12.76B |
| Total Current Liabilities | 34.15B | 32.72B | 33.89B |
| Total Liabilities | 113.73B | 113.37B | 101B |
| Long Term Debt | 49.79B | 50.53B | 36.28B |
| Current Long Term Debt | 13.36B | 1.48B | 337M |
| Minority Interest | 236M | 8M | 9M |
| Common Stock | 88.63B | 5.55B | 5.55B |
| Treasury Stock | -110.98B | 110.98B | 111.01B |
| Retained Earnings | 100.28B | 100.20B | 101B |
| Capital Surplus | N.A | 87.89B | 87.68B |
| Shareholder Equity | 65.26B | 64.34B | 65.03B |
| Other Liabilities | N.A | N.A | N.A |
Pfizer Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 1.31B | 2.79B | 1.78B | 1.94B |
| Receivables | 8.72B | 9.44B | 9.79B | 9.60B |
| Inventory | 8.28B | 8.22B | 8.23B | 8.03B |
| Current Assets | 32.80B | 33.46B | 47.07B | 45.29B |
| Other Current Assets | 5.97B | 6.71B | 16.14B | 16.04B |
| Short Term Investments | 8.53B | 6.30B | 11.13B | 9.68B |
| Long Term Investments | 20.15B | 18.72B | 2.91B | 2.86B |
| Property/Plant Equipment | 15.28B | 15.01B | 14.79B | 14.75B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 35.37B | 39B | 33.02B | 34.04B |
| Tangible Assets (Net) | -154.57B | -155.16B | -142.99B | -143.99B |
| Other Assets | 3.14B | 3.61B | 3.12B | 3.05B |
| Total Assets | 167.49B | 170.45B | 156.20B | 155.42B |
| Accounts Payable | 4.22B | 3.94B | 4B | 4.16B |
| Other Current Liabilities | 15.63B | 14.24B | 15.72B | 13.76B |
| Total Current Liabilities | 37.30B | 36.97B | 32.03B | 29.42B |
| Total Liabilities | 104.04B | 105.05B | 96.27B | 96.26B |
| Long Term Debt | 37B | 37.08B | 37.19B | 36.78B |
| Current Long Term Debt | 1.46B | 2.43B | 2.14B | 4.47B |
| Minority Interest | 10M | 4M | 10M | 6M |
| Common Stock | 5.53B | 5.53B | 5.56B | 5.56B |
| Treasury Stock | 110.80B | 110.80B | 110.79B | 110.78B |
| Retained Earnings | 97.67B | 100.11B | 94.44B | 93.39B |
| Capital Surplus | 87.43B | 87.10B | 86.96B | 86.64B |
| Shareholder Equity | 63.14B | 65.10B | 59.57B | 58.81B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Pfizer Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 1.17B | 3.56B | 2.70B | 2.30B |
| Receivables | 8.03B | 10.02B | 9.87B | 9.45B |
| Inventory | 7.51B | 8.18B | 8.07B | 8.15B |
| Current Assets | 49.93B | 41.58B | 37.30B | 34.84B |
| Other Current Assets | 15.56B | 6.14B | 5.93B | 5.81B |
| Short Term Investments | 17.66B | 13.68B | 10.73B | 9.12B |
| Long Term Investments | 2.77B | 6.44B | 6.60B | 6.95B |
| Property/Plant Equipment | 13.39B | 14.04B | 13.92B | 13.97B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 35.21B | 45.31B | 46.58B | 47.69B |
| Tangible Assets (Net) | -139.37B | -145.39B | -147.65B | -148.75B |
| Other Assets | 2.80B | 2.98B | 2.90B | 2.90B |
| Total Assets | 159.42B | 167.84B | 164.98B | 164.61B |
| Accounts Payable | 4.67B | 4.30B | 4.20B | 3.88B |
| Other Current Liabilities | 17.09B | 14.55B | 13.90B | 12.86B |
| Total Current Liabilities | 31.86B | 29.01B | 32.16B | 27.37B |
| Total Liabilities | 95.66B | 96.17B | 94.86B | 94.07B |
| Long Term Debt | 32.91B | 33.65B | 28.94B | 31.83B |
| Current Long Term Debt | 4.78B | 4.26B | 4.26B | 4.76B |
| Minority Interest | 11M | 8M | 7M | 9M |
| Common Stock | 5.72B | 5.78B | 5.86B | 5.85B |
| Treasury Stock | 101.61B | 96.57B | 95.46B | 95.46B |
| Retained Earnings | 89.55B | 91.99B | 89.86B | 89.96B |
| Capital Surplus | 86.25B | 85.83B | 84.90B | 84.60B |
| Shareholder Equity | 63.41B | 71.32B | 69.78B | 70.18B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Pfizer Inc. balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 1.34B | 2.78B | 2.59B |
| Receivables | 8.22B | 10B | 9.48B |
| Inventory | 7.58B | 7.93B | 7.58B |
| Current Assets | 41.14B | 40.29B | 36.39B |
| Other Current Assets | 5.35B | 5.44B | 4.99B |
| Short Term Investments | 18.65B | 14.15B | 11.75B |
| Long Term Investments | 7.02B | 7.31B | 7.01B |
| Property/Plant Equipment | 13.87B | 13.51B | 13.39B |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 48.74B | 49.72B | 51.35B |
| Tangible Assets (Net) | -146.37B | -157.27B | -157.5B |
| Other Assets | 3.23B | 3.39B | 3.47B |
| Total Assets | 171.80B | 172.15B | 168.56B |
| Accounts Payable | 4.66B | 3.48B | 3.44B |
| Other Current Liabilities | 15.34B | 14.29B | 13.68B |
| Total Current Liabilities | 30.43B | 28.22B | 27.18B |
| Total Liabilities | 100.14B | 111.04B | 109.86B |
| Long Term Debt | 33.54B | 34.50B | 34.19B |
| Current Long Term Debt | 3.55B | 3.07B | 3.07B |
| Minority Interest | 15M | 18M | 5M |
| Common Stock | 5.98B | 5.96B | 5.95B |
| Treasury Stock | 89.43B | 89.42B | 89.42B |
| Retained Earnings | 85.29B | 75.04B | 74.11B |
| Capital Surplus | 84.28B | 83.83B | 83.37B |
| Shareholder Equity | 71.31B | 60.77B | 58.37B |
| Other Liabilities | N.A | N.A | N.A |
Pfizer Inc. cash flow (2020) (USD)
| November 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Net Income | 2.19B | 3.43B | 3.40B |
| Depreciation | 3.73B | 1.25B | 1.22B |
| Changes in Receivables | 884M | 753M | -1.16B |
| Changes in Inventories | 731M | N.A | N.A |
| Cash Change | -883M | -352M | 847M |
| Cash Flow | 8.78B | 3.55B | 3.13B |
| Capital Expenditures | -1.51B | -480M | -495M |
| Investments | N.A | -12.55B | 420M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -12.6B | -13.01B | -71M |
| Dividends Paid | N.A | -2.11B | -2.11B |
| Net Borrowings | 46.13B | 11.32B | 18M |
| Other Financing Cash Flows | N.A | -84M | -237M |
| Cash Flow Financing | 4.14B | 9.16B | -2.2B |
| Exchange Rate Effect | N.A | -55M | -15M |
Pfizer Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | -337M | 7.68B | 5.05B | 3.88B |
| Depreciation | 1.38B | 1.55B | 1.53B | 1.55B |
| Changes in Receivables | 715M | 354M | -194M | -1.57B |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | -1.5B | 1.01B | -182M | 793M |
| Cash Flow | 3.77B | 4.51B | 2.61B | 1.70B |
| Capital Expenditures | -726M | -662M | -588M | -618M |
| Investments | -2.17B | 4.80B | -1.43B | 8.10B |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -2.83B | -6.76B | -1.9B | 7.55B |
| Dividends Paid | -1.99B | -2B | -2B | -2.05B |
| Net Borrowings | -470M | 5.35B | 1.07B | 2.81B |
| Other Financing Cash Flows | -69M | -125M | -45M | -496M |
| Cash Flow Financing | -2.44B | 3.27B | -851M | -8.47B |
| Exchange Rate Effect | 9M | -13M | -40M | 12M |
Pfizer Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | -394M | 4.11B | 3.87B | 3.56B |
| Depreciation | 1.64B | 1.61B | 1.56B | 1.57B |
| Changes in Receivables | 2B | -151M | -421M | -1.23B |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | -2.43B | 848M | 395M | 0.99B |
| Cash Flow | 4.74B | 5.26B | 3.85B | 1.98B |
| Capital Expenditures | -792M | -562M | -456M | -386M |
| Investments | -10M | -2.45B | -1.13B | 10.03B |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -764M | -2.9B | -1.47B | 9.67B |
| Dividends Paid | -1.96B | -1.99B | -1.99B | -2.03B |
| Net Borrowings | 462M | 790M | 316M | -2.5B |
| Other Financing Cash Flows | -36M | 278M | -337M | -494M |
| Cash Flow Financing | -6.41B | -1.41B | -1.91B | -10.72B |
| Exchange Rate Effect | N.A | -101M | -70M | 55M |
Pfizer Inc. cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | 12.27B | 2.84B | 3.07B |
| Depreciation | 1.57B | 1.57B | 1.57B |
| Changes in Receivables | 1.78B | -526M | -584M |
| Changes in Inventories | N.A | N.A | N.A |
| Cash Change | -1.44B | 194M | -1.47B |
| Cash Flow | 6.74B | 4.89B | 3.25B |
| Capital Expenditures | -773M | -597M | -489M |
| Investments | -4.14B | -2.46B | -0.99B |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -4.78B | -3B | -1.74B |
| Dividends Paid | -1.91B | -1.9B | -1.91B |
| Net Borrowings | -1.67B | -84M | -1.18B |
| Other Financing Cash Flows | -10M | 5M | -8M |
| Cash Flow Financing | -3.39B | -1.73B | -3B |
| Exchange Rate Effect | -14M | 30M | 16M |
Pfizer Inc. dividends (USD)
| Ex date | Payment date | Record date | Declared date | Amount | Description | Frequency |
|---|---|---|---|---|---|---|
| 05-11-2020 | 01-12-2020 | 06-11-2020 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 30-07-2020 | 01-09-2020 | 31-07-2020 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 30-07-2020 | 01-09-2020 | 31-07-2020 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 07-05-2020 | 05-06-2020 | 08-05-2020 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 30-01-2020 | 06-03-2020 | 31-01-2020 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 07-11-2019 | 02-12-2019 | 08-11-2019 | N.A | 0.36 | Ordinary Shares | Quarterly |
| 01-08-2019 | 03-09-2019 | 02-08-2019 | N.A | 0.36 | Ordinary Shares | Quarterly |
| 09-05-2019 | 07-06-2019 | 10-05-2019 | N.A | 0.36 | Ordinary Shares | Quarterly |
| 31-01-2019 | 01-03-2019 | 01-02-2019 | N.A | 0.36 | Ordinary Shares | Quarterly |
| 08-11-2018 | 03-12-2018 | 09-11-2018 | N.A | 0.34 | Ordinary Shares | Quarterly |
| 02-08-2018 | 04-09-2018 | 03-08-2018 | N.A | 0.34 | Ordinary Shares | Quarterly |
| 10-05-2018 | 01-06-2018 | 11-05-2018 | N.A | 0.34 | Ordinary Shares | Quarterly |
| 01-02-2018 | 01-03-2018 | 02-02-2018 | N.A | 0.34 | Ordinary Shares | Quarterly |
| 09-11-2017 | 01-12-2017 | 10-11-2017 | N.A | 0.32 | Ordinary Shares | Quarterly |
| 02-08-2017 | 01-09-2017 | 04-08-2017 | N.A | 0.32 | Ordinary Shares | Quarterly |
| 10-05-2017 | 01-06-2017 | 12-05-2017 | N.A | 0.32 | Ordinary Shares | Quarterly |
| 01-02-2017 | 01-03-2017 | 03-02-2017 | N.A | 0.32 | Ordinary Shares | Quarterly |
| 08-11-2016 | 01-12-2016 | 11-11-2016 | N.A | 0.30 | Ordinary Shares | Quarterly |
| 03-08-2016 | 01-09-2016 | 05-08-2016 | N.A | 0.30 | Ordinary Shares | Quarterly |
| 11-05-2016 | 01-06-2016 | 13-05-2016 | N.A | 0.30 | Ordinary Shares | Quarterly |
| 03-02-2016 | 02-03-2016 | 05-02-2016 | N.A | 0.30 | Ordinary Shares | Quarterly |
| 04-11-2015 | 01-12-2015 | 06-11-2015 | N.A | 0.28 | Ordinary Shares | Quarterly |
| 05-08-2015 | 02-09-2015 | 07-08-2015 | N.A | 0.28 | Ordinary Shares | Quarterly |
Insider Roster
| Entity name | Report date | Shares held |
|---|---|---|
| YOUNG JOHN D | 30-12-2020 | 415,947 |
| BOURLA ALBERT | 16-12-2020 | 83,477 |
| SUSMAN SALLY | 10-11-2020 | 108,096 |
| KILTS JAMES M | 28-09-2020 | 186,391 |
| Dolsten Mikael | 19-05-2020 | 174,918 |
| CORNWELL W DON | 24-04-2020 | 138,711 |
| NORA JOHNSON SUZANNE M | 24-04-2020 | 73,959 |
Insider Summary
| Full name | Reported title | Total bought | Total sold | Net transacted |
|---|---|---|---|---|
| Fonseca Lidia | Executive Vice President | 256,232 | 12,086 | 244,146 |
Insider Transactions
| Full name | Reported title | Effective date | Amount of shares | Price per share | Total cost |
|---|---|---|---|---|---|
| YOUNG JOHN D | Group President | 29-12-2020 | -10,607 | 37.05 | 392,989.00 |
| LANKLER DOUGLAS M | Executive Vice President | 16-12-2020 | -5,442 | 37.84 | 205,925.00 |
| Hwang Angela | Group President | 16-12-2020 | -12,970 | 37.84 | 490,785.00 |
| JOHNSON RADY A | Executive Vice President | 16-12-2020 | -661 | N.A | N.A |
| DAMICO JENNIFER B. | SVP & Controller | 15-12-2020 | +31 | 38.71 | +1,200.01 |
| BOURLA ALBERT | Chairman & CEO | 15-12-2020 | +12 | 38.71 | +464.52 |
| JOHNSON RADY A | Executive Vice President | 15-12-2020 | +4 | 38.71 | +154.84 |
| YOUNG JOHN D | Group President | 15-12-2020 | +11 | 38.71 | +425.81 |
| JOHNSON RADY A | Executive Vice President | 30-11-2020 | +4 | 38.31 | +153.24 |
| BOURLA ALBERT | Chairman & CEO | 30-11-2020 | +13 | 38.31 | +498.03 |
| YOUNG JOHN D | Group President | 30-11-2020 | +11 | 38.31 | +421.41 |
| DAMICO JENNIFER B. | SVP & Controller | 30-11-2020 | +31 | 38.31 | +1,187.61 |
| BOURLA ALBERT | Chairman & CEO | 13-11-2020 | +12 | 38.62 | +463.44 |
| YOUNG JOHN D | Group President | 13-11-2020 | +11 | 38.62 | +424.82 |
| DAMICO JENNIFER B. | SVP & Controller | 13-11-2020 | +31 | 38.62 | +1,197.22 |
| JOHNSON RADY A | Executive Vice President | 13-11-2020 | +4 | 38.62 | +154.48 |
| SUSMAN SALLY | Executive Vice President | 09-11-2020 | -43,662 | 41.94 | 1,831,180.00 |
| BOURLA ALBERT | Chairman & CEO | 09-11-2020 | -132,508 | 41.94 | 5,557,390.00 |
| DAMICO JENNIFER B. | SVP & Controller | 30-10-2020 | +33 | 35.48 | +1,170.84 |
| YOUNG JOHN D | Group President | 30-10-2020 | +12 | 35.48 | +425.76 |
| BOURLA ALBERT | Chairman & CEO | 30-10-2020 | +14 | 35.48 | +496.72 |
| JOHNSON RADY A | Executive Vice President | 30-10-2020 | +5 | 35.48 | +177.40 |
| BOURLA ALBERT | Chairman & CEO | 15-10-2020 | +13 | 36.55 | +475.15 |
| JOHNSON RADY A | Executive Vice President | 15-10-2020 | +4 | 36.55 | +146.20 |
| DAMICO JENNIFER B. | SVP & Controller | 15-10-2020 | +32 | 36.55 | +1,169.60 |
| YOUNG JOHN D | Group President | 15-10-2020 | +12 | 36.55 | +438.60 |
| JOHNSON RADY A | Executive Vice President | 12-10-2020 | +20 | 36.82 | +736.40 |
| DAMICO JENNIFER B. | SVP & Controller | 12-10-2020 | +145 | 36.82 | +5,338.90 |
| YOUNG JOHN D | Group President | 12-10-2020 | +40 | 36.82 | +1,472.80 |
| BOURLA ALBERT | Chairman & CEO | 12-10-2020 | +50 | 36.82 | +1,841.00 |
| YOUNG JOHN D | Group President | 30-09-2020 | +12 | 36.70 | +440.40 |
| JOHNSON RADY A | Executive Vice President | 30-09-2020 | +4 | 36.70 | +146.80 |
| DAMICO JENNIFER B. | SVP & Controller | 30-09-2020 | +32 | 36.70 | +1,174.40 |
| BOURLA ALBERT | Chairman & CEO | 30-09-2020 | +13 | 36.70 | +477.10 |
| YOUNG JOHN D | Group President | 15-09-2020 | +12 | 36.96 | +443.52 |
| DAMICO JENNIFER B. | SVP & Controller | 15-09-2020 | +32 | 36.96 | +1,182.72 |
| JOHNSON RADY A | Executive Vice President | 15-09-2020 | +4 | 36.96 | +147.84 |
| BOURLA ALBERT | Chairman & CEO | 15-09-2020 | +13 | 36.96 | +480.48 |
| DAMICO JENNIFER B. | SVP & Controller | 31-08-2020 | +31 | 37.79 | +1,171.49 |
| JOHNSON RADY A | Executive Vice President | 31-08-2020 | +4 | 37.79 | +151.16 |
| YOUNG JOHN D | Group President | 31-08-2020 | +11 | 37.79 | +415.69 |
| BOURLA ALBERT | Chairman & CEO | 31-08-2020 | +13 | 37.79 | +491.27 |
| YOUNG JOHN D | Group President | 14-08-2020 | +11 | 38.06 | +418.66 |
| BOURLA ALBERT | Chairman & CEO | 14-08-2020 | +13 | 38.06 | +494.78 |
| DAMICO JENNIFER B. | SVP & Controller | 14-08-2020 | +31 | 38.06 | +1,179.86 |
| JOHNSON RADY A | Executive Vice President | 14-08-2020 | +4 | 38.06 | +152.24 |
| BLAYLOCK RONALD E | N.A | 06-08-2020 | +1,000 | 38.62 | +38,620.00 |
| JOHNSON RADY A | Executive Vice President | 31-07-2020 | +4 | 38.48 | +153.92 |
| BOURLA ALBERT | Chairman & CEO | 31-07-2020 | +13 | 38.48 | +500.24 |
| DAMICO JENNIFER B. | SVP & Controller | 31-07-2020 | +31 | 38.48 | +1,192.88 |
| YOUNG JOHN D | Group President | 31-07-2020 | +11 | 38.48 | +423.28 |
| BOURLA ALBERT | Chairman & CEO | 15-07-2020 | +13 | 35.72 | +464.36 |
| JOHNSON RADY A | Executive Vice President | 15-07-2020 | +4 | 35.72 | +142.88 |
| YOUNG JOHN D | Group President | 15-07-2020 | +12 | 35.72 | +428.64 |
| DAMICO JENNIFER B. | SVP & Controller | 15-07-2020 | +33 | 35.72 | +1,178.76 |
| BOURLA ALBERT | Chairman & CEO | 09-07-2020 | +55 | 33.46 | +1,840.30 |
| DAMICO JENNIFER B. | SVP & Controller | 09-07-2020 | +160 | 33.46 | +5,353.60 |
| YOUNG JOHN D | Group President | 09-07-2020 | +44 | 33.46 | +1,472.24 |
| JOHNSON RADY A | Executive Vice President | 09-07-2020 | +22 | 33.46 | +736.12 |
| BOURLA ALBERT | Chairman & CEO | 30-06-2020 | +15 | 32.70 | +490.50 |
| YOUNG JOHN D | Group President | 30-06-2020 | +13 | 32.70 | +425.10 |
| JOHNSON RADY A | Executive Vice President | 30-06-2020 | +5 | 32.70 | +163.50 |
| DAMICO JENNIFER B. | SVP & Controller | 30-06-2020 | +36 | 32.70 | +1,177.20 |
| YOUNG JOHN D | Group President | 30-06-2020 | +13 | 32.70 | +425.10 |
| JOHNSON RADY A | Executive Vice President | 15-06-2020 | +5 | 33.36 | +166.80 |
| YOUNG JOHN D | Group President | 15-06-2020 | +13 | 33.36 | +433.68 |
| DAMICO JENNIFER B. | SVP & Controller | 15-06-2020 | +36 | 33.36 | +1,200.96 |
| ROGERS DAWN | Executive Vice President | 15-06-2020 | +60 | 33.36 | +2,001.60 |
| BOURLA ALBERT | Chairman & CEO | 15-06-2020 | +14 | 33.36 | +467.04 |
| DAMICO JENNIFER B. | SVP & Controller | 05-06-2020 | -2,181 | 36.13 | 78,799.50 |
| YOUNG JOHN D | Group President | 29-05-2020 | +11 | 38.19 | +420.09 |
| BOURLA ALBERT | Chairman & CEO | 29-05-2020 | +13 | 38.19 | +496.47 |
| JOHNSON RADY A | Executive Vice President | 29-05-2020 | +4 | 38.19 | +152.76 |
| DAMICO JENNIFER B. | SVP & Controller | 29-05-2020 | +31 | 38.19 | +1,183.89 |
| ROGERS DAWN | Executive Vice President | 29-05-2020 | +52 | 38.19 | +1,985.88 |
| Dolsten Mikael | President R&D | 18-05-2020 | -24,242 | 37.79 | 916,105.00 |
| YOUNG JOHN D | Group President | 15-05-2020 | +11 | 37.76 | +415.36 |
| JOHNSON RADY A | Executive Vice President | 15-05-2020 | +4 | 37.76 | +151.04 |
| ROGERS DAWN | Executive Vice President | 15-05-2020 | +53 | 37.76 | +2,001.28 |
| DAMICO JENNIFER B. | SVP & Controller | 15-05-2020 | +31 | 37.76 | +1,170.56 |
| BOURLA ALBERT | Chairman & CEO | 15-05-2020 | +13 | 37.76 | +490.88 |
| BOURLA ALBERT | Chairman & CEO | 30-04-2020 | +13 | 38.36 | +498.68 |
| ROGERS DAWN | Executive Vice President | 30-04-2020 | +52 | 38.36 | +1,994.72 |
| JOHNSON RADY A | Executive Vice President | 30-04-2020 | +4 | 38.36 | +153.44 |
| YOUNG JOHN D | Group President | 30-04-2020 | +11 | 38.36 | +421.96 |
| DAMICO JENNIFER B. | SVP & Controller | 30-04-2020 | +31 | 38.36 | +1,189.16 |
| ROGERS DAWN | Executive Vice President | 29-04-2020 | -13,000 | 38.13 | 495,690.00 |
| YOUNG JOHN D | Group President | 29-04-2020 | -7,910 | N.A | N.A |
| JOHNSON RADY A | Executive Vice President | 29-04-2020 | -13,125 | 38.36 | 503,475.00 |
| LANKLER DOUGLAS M | Executive Vice President | 29-04-2020 | -57,099 | 37.83 | 2,160,060.00 |
| DAMICO JENNIFER B. | SVP & Controller | 29-04-2020 | -2,181 | 38.35 | 83,641.40 |
| ROGERS DAWN | Executive Vice President | 15-04-2020 | +56 | 35.97 | +2,014.32 |
| YOUNG JOHN D | Group President | 15-04-2020 | +12 | 35.97 | +431.64 |
| DAMICO JENNIFER B. | SVP & Controller | 15-04-2020 | +33 | 35.97 | +1,187.01 |
| JOHNSON RADY A | Executive Vice President | 15-04-2020 | +4 | 35.97 | +143.88 |
| BOURLA ALBERT | Chairman & CEO | 15-04-2020 | +13 | 35.97 | +467.61 |
| DAMICO JENNIFER B. | SVP & Controller | 08-04-2020 | +60 | 34.60 | +2,076.00 |
| BOURLA ALBERT | Chairman & CEO | 08-04-2020 | +489 | 34.60 | +16,919.40 |
| JOHNSON RADY A | Executive Vice President | 08-04-2020 | +49 | 34.60 | +1,695.40 |
| YOUNG JOHN D | Group President | 08-04-2020 | +222 | 34.60 | +7,681.20 |